Schonfeld Strategic Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $273K | Sell |
3,411
-93,980
| -96% | -$7.75M | ﹤0.01% | 1615 |
|
|
2025
Q4 | $8.3M | Sell |
97,391
-118,894
| -55% | -$9.76M | 0.04% | 394 |
|
|
2025
Q3 | $16.8M | Buy |
216,285
+93,778
| +77% | +$7.33M | 0.1% | 225 |
|
|
2025
Q2 | $9.58M | Sell |
122,507
-338,741
| -73% | -$25.3M | 0.07% | 354 |
|
|
2025
Q1 | $33.4M | Buy |
461,248
+339,862
| +280% | +$24.3M | 0.2% | 70 |
|
|
2024
Q4 | $8.99M | Buy |
121,386
+70,201
| +137% | +$4.91M | 0.05% | 325 |
|
|
2024
Q3 | $3.38M | Buy |
+51,185
| New | +$3.72M | 0.02% | 676 |
|
|
2023
Q4 | – | Sell |
-181,691
| Closed | -$12.6M | – | 1972 |
|
|
2023
Q3 | $12.6M | Buy |
181,691
+173,904
| +2,233% | +$14M | 0.1% | 291 |
|
|
2023
Q2 | $735K | Buy |
+7,787
| New | +$677K | 0.01% | 1086 |
|
|
2022
Q4 | – | Sell |
-183,500
| Closed | -$15.2M | – | 2703 |
|
|
2022
Q3 | $15.2M | Buy |
+183,500
| New | +$17.7M | 0.13% | 227 |
|
|
2022
Q2 | – | Sell |
-118
| Closed | -$14K | – | 2653 |
|
|
2022
Q1 | $14K | Buy |
+118
| New | +$13.2K | ﹤0.01% | 2408 |
|
|
2021
Q4 | – | Sell |
-12,100
| Closed | -$1.37M | – | 2252 |
|
|
2021
Q3 | $1.37M | Sell |
12,100
-46,342
| -79% | -$5.29M | 0.01% | 841 |
|
|
2021
Q2 | $6.05M | Buy |
+58,442
| New | +$5.51M | 0.06% | 410 |
|
|
2021
Q1 | – | Sell |
-17,900
| Closed | -$1.63M | – | 1885 |
|
|
2020
Q4 | $1.63M | Sell |
17,900
-36,830
| -67% | -$3.05M | 0.02% | 656 |
|
|
2020
Q3 | $4.37M | Sell |
54,730
-30,206
| -36% | -$2.36M | 0.08% | 325 |
|
|
2020
Q2 | $5.87M | Buy |
+84,936
| New | +$6.04M | 0.15% | 201 |
|
|
2020
Q1 | – | Sell |
-81,300
| Closed | -$6.32M | – | 1246 |
|
|
2019
Q4 | $6.32M | Buy |
+81,300
| New | +$6.35M | 0.15% | 162 |
|
|
2019
Q3 | – | Sell |
-211,416
| Closed | -$13M | – | 1078 |
|
|
2019
Q2 | $13M | Buy |
211,416
+199,281
| +1,642% | +$12.1M | 0.46% | 51 |
|
|
2019
Q1 | $774K | Sell |
12,135
-10,365
| -46% | -$592K | 0.03% | 573 |
|
|
2018
Q4 | $1.15M | Buy |
+22,500
| New | +$1.14M | 0.04% | 445 |
|
|
2018
Q3 | – | Sell |
-98,658
| Closed | -$4.79M | – | 858 |
|
|
2018
Q2 | $4.79M | Sell |
98,658
-163,851
| -62% | -$7.65M | 0.26% | 128 |
|
|
2018
Q1 | $12.2M | Sell |
262,509
-10,479
| -4% | -$455K | 0.92% | 9 |
|
|
2017
Q4 | $10.3M | Buy |
272,988
+62,955
| +30% | +$2.31M | 0.84% | 8 |
|
|
2017
Q3 | $7.65M | Buy |
210,033
+204,180
| +3,488% | +$7.79M | 0.7% | 23 |
|
|
2017
Q2 | $231K | Sell |
5,853
-55,065
| -90% | -$2.01M | 0.02% | 529 |
|
|
2017
Q1 | $1.91M | Sell |
60,918
-76,902
| -56% | -$2.41M | 0.19% | 152 |
|
|
2016
Q4 | $4.3M | Buy |
+137,820
| New | +$4.47M | 0.56% | 41 |
|
|
2016
Q3 | – | Sell |
-33,045
| Closed | -$1.1M | – | 454 |
|
|
2016
Q2 | $1.1M | Buy |
33,045
+24,828
| +302% | +$849K | 0.25% | 116 |
|
|
2016
Q1 | $242K | Buy |
+8,217
| New | +$227K | 0.1% | 248 |
|
Other funds holding EW
VCM
VPM
Schonfeld Strategic Advisors's EW Position: Q1 2026 in Review
Schonfeld Strategic Advisors reduced its Edwards Lifesciences (EW) stake by 96% in Q1 2026, selling an estimated $7.75M and leaving 3,411 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #1615.
Schonfeld Strategic Advisors first reported a position in EW in Q1 2016 and has held it in 29 quarters since. The position peaked at $33.4M in Q1 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Schonfeld Strategic Advisors held 3,411 shares of Edwards Lifesciences worth $273K as of Q1 2026.
- Schonfeld Strategic Advisors sold 93,980 Edwards Lifesciences shares in Q1 2026, an estimated $7.75M.
- Edwards Lifesciences made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1615 holding.
- Schonfeld Strategic Advisors first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 29 quarters since.
- Schonfeld Strategic Advisors's Edwards Lifesciences position peaked at $33.4M in Q1 2025.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.